{"id":"arbaclofen-placarbil-mr-prototype-b","_chembl":{"chemblId":"CHEMBL2107312","moleculeType":"Small molecule","molecularWeight":"399.87"},"modality":"Small molecule","_dailymed":null,"mechanism":{"target":"GABA-B receptor","explanation":"Upon administration, arbaclofen placarbil is absorbed and converted to arbaclofen, the pharmacologically active R-enantiomer of baclofen. Arbaclofen selectively activates GABA-B receptors, inhibiting neurotransmitter release and reducing neuronal excitability. The modified-release formulation aims to provide sustained drug exposure.","oneSentence":"Arbaclofen placarbil is a prodrug that is converted to arbaclofen, a GABA-B receptor agonist that modulates neurotransmission in the central nervous system."},"_scrapedAt":"2026-03-28T04:54:10.627Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123119,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"baclofen","brand":"Lioresal","company":null,"rationale":"Standard GABA-B agonist for spasticity and related conditions"},{"name":"arbaclofen","brand":null,"company":null,"rationale":"Active enantiomer, investigated for similar GABA-B mediated indications"}],"description":"Arbaclofen Placarbil MR Prototype B is an investigational modified-release prodrug formulation developed by Indivior Inc. currently in Phase 1 clinical testing. It is designed as a prodrug of arbaclofen, the active R-enantiomer of baclofen, intended to improve drug delivery and pharmacokinetic properties.","indications":{"approved":[{"status":"investigational","condition":"Unknown indication under investigation","patientPopulation":null}]},"trialDetails":[{"nctId":"NCT03058237","phase":"PHASE1","title":"A Phase 1 Bioavailability Study of Arbaclofen Placarbil Modified Release Formulations in Healthy Volunteers","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2017-01-24","conditions":"Healthy Volunteers","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"Arbaclofen Placarbil MR Prototype B","genericName":"Arbaclofen Placarbil MR Prototype B","companyName":"Indivior Inc.","companyId":"indivior-inc","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}